On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Beam Therapeutics (NASDAQ:BEAM) fell sharply in the morning hours Tuesday after multiple media reports indicated that a patient has died following the administration of the company's experimental gene ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been ...

It’s a rare condition triggered by exercise that is too intense in someone with the sickle cell trait, a sickle cell gene inherited from just one parent. Such exercise can cause the body’s red blood ...

Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle ...

NEW YORK – Beam Therapeutics on Tuesday disclosed initial clinical data, including one patient death, in a Phase I/II trial of its investigational sickle cell disease (SCD) gene-editing therapy ...